These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Photocarcinogenesis in mice by 4,4',6 trimethylangelicin plus UVA radiation.
    Author: Alcalay J, Dall'Acqua F, Kripke ML.
    Journal: Photodermatol Photoimmunol Photomed; 1990 Jun; 7(3):116-8. PubMed ID: 2081117.
    Abstract:
    The carcinogenic effect of a new monofunctional psoralen 4,4',6-trimethylangelicin (TMA) plus UVA radiation was examined in C3H/HeN mice and compared with that of the parent compound angelicin. TMA carcinogenic effects were also compared with the previously reported effects of 8-methoxypsoralen. Using 2 different doses of TMA (25 micrograms and 250 micrograms) combined with 1 J/cm2 of UVA radiation, we found that 42% and 52% of the mice (respectively) developed tumors on the treated site. A dose of angelicin (215 micrograms) equimolar to the highest dose of TMA combined with 1 J/cm2 of UVA radiation produced tumors in 28% of the mice (P greater than 0.05). All tumors were squamous cell carcinomas. No metastases were found in any of the mice. We conclude that, although TMA + UVA radiation is carcinogenic in mice, it seems to be an equally active, but less phototoxic and less carcinogenic psoralen than 8-methoxypsoralen. The parent compound angelicin is not significantly less carcinogenic, and its clinical efficacy is poor.
    [Abstract] [Full Text] [Related] [New Search]